UnitedHealth Group's shares surged in early trading after the health insurer and services provider posted second-quarter results that materially exceeded analyst forecasts on multiple fronts. Adjusted earnings came in at $6.38 per share for Q2 2026 - more than $1.50 above the consensus of about $4.85 - while revenue reached $112.0 billion, topping expectations of $110.76 billion.
Perhaps most consequential to investors was the sizable improvement in the company's medical care ratio, which declined to 86.7% in the quarter from 89.4% a year earlier. That outcome was notably stronger than the roughly 88.6% analysts had expected. The medical care ratio, which reflects the portion of premium revenue used to pay medical claims, has been a focal point for shareholders during the company's recent turnaround efforts. The quarter's lower ratio signaled to the market that previously elevated cost pressures may be receding.
Management also raised its full-year 2026 adjusted earnings-per-share guidance to a range of $19.50 to $20.00, exceeding both the company's prior outlook and the analyst consensus of roughly $18.48. Company commentary cited strong performance in the Optum segment as a key factor behind the upward revision.
On the analyst side, Piper Sandler had already boosted its price target on UnitedHealth to $475 from $420 ahead of the earnings release, while maintaining an Overweight rating and pointing to confidence in Medicare Advantage outperformance as a foundational thesis for the higher target.
The run-up in UnitedHealth shares reversed a cautious pre-earnings tone. The stock had dipped in the session prior following sector-level pressure after peer Elevance Health published results that highlighted persistent Medicaid margin challenges. The company's blowout quarter and guidance lift effectively flipped sentiment across the managed-care group.
The broader U.S. equity market offered little help to the move, with the S&P 500 edging down 0.2%, the Nasdaq falling 0.6% and the Dow Jones Industrial Average modestly positive at 0.2% on the same trading day. Despite that muted market backdrop, UnitedHealth traded at $450.55 - positioning it above its prior 52-week high of $434.30 - as investors re-rated the stock on the back of the results.
In sum, a sizeable earnings beat, an unexpectedly favorable medical care ratio and a second guidance increase for 2026 combined to produce a sharp pre-market re-pricing of UnitedHealth. The results appear to have reinforced the view that the company's multi-year operational recovery is gaining traction, with Optum's contribution highlighted by management as an important driver.
Note: The article presents reported financial figures, guidance and market reactions as disclosed in the company's quarterly release and accompanying commentary. It does not introduce information beyond those reported figures and statements.